New Care Organizations, Board Appointments, and Strong Top Line Growth Reports - Research Report on UnitedHealth, WellPoint, WellCare, ARIAD, and DexCom

NEW YORK, August 12, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting UnitedHealth Group Inc. (NYSE: UNH), WellPoint, Inc. (NYSE: WLP), WellCare Health Plans, Inc. (NYSE: WCG), ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and DexCom, Inc. (NASDAQ: DXCM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

UnitedHealth Group Inc. Research Report

On August 1, 2013, UnitedHealthcare, a business segment of UnitedHealth Group Inc. (UnitedHealth), and Mount Carmel Health Partners announced an accountable care organization (ACO) that will provide coordinated healthcare to Central Ohio residents enrolled in UnitedHealthcare's employer-sponsored health plans starting from October 1, 2013. UnitedHealth stated that the new ACO model will help shift the Central Ohio healthcare system from one that rewards for number of patients treated to one that rewards to one that rewards quality and value. According to the Company, the new ACO collaboration will help participating physicians and Mount Carmel's four hospitals improve transitions of care for patients and facilitate better communication with other medical providers involved in a patient's treatment. The Company also informed that UnitedHealthcare plan participants, which total up to more than 20,000, will not have to do anything differently to receive ACO benefits, which include enhanced care coordination and follow ups. The Full Research Report on UnitedHealth Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-07/UNH]

--

WellPoint, Inc. Research Report

On August 7, 2013, WellPoint, Inc. (WellPoint) announced that Jill Rubin Hummel, the Company's Vice President of Payment Innovation, was appointed to serve on the Board of Directors for the Patient-Centered Primary Care Collaborative (PCPCC). Commenting on the appointment, Doug Wenners, Senior Vice President of Provider Engagement and Contracting for WellPoint, said, "We are extremely proud of Jill Hummel's leadership in advancing the goals of patient-centered care, particularly in primary care settings. These ideas are at the center of WellPoint's own work to contribute to a more affordable, less costly health care system that delivers a better experience for health plan members." WellPoint also informed that the other new members of PCPCC's Board of Directors include: Elizabeth J. Fowler, Vice President of Global Health Policy, Johnson and Johnson; Hal C. Lawrence, Executive Vice President, American College of Obstetricians and Gynecologists, and Adrienne White-Faines, Executive Director of the American Osteopathic Association. The Full Research Report on WellPoint, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-07/WLP]

--

WellCare Health Plans, Inc. Research Report

On August 7, 2013, WellCare Health Plans, Inc. (WellCare) reported its Q2 2013 results. The Company's total revenues increased 28.8% YoY to $2.3 billion, driven by a 67% YoY increase in Medicare Advantage segment premium revenue and a 26%YoY increase in Medicaid segment premium revenue. Net income was $46.9 million or $1.07 per diluted share in Q2 2013, compared to net income of $46.4 million or $1.06 per diluted share in Q2 2012. Commenting on the results, Alec Cunningham, WellCare's CEO, said, "Our second quarter results reflect the ongoing strengthening of our quality, service, and productivity, as well as execution on acquisition integration and organic growth. We see important opportunities for growth in 2014 and beyond and are continuing to invest in our capabilities to capitalize on those opportunities."The Full Research Report on WellCare Health Plans, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-07/WCG]

--

ARIAD Pharmaceuticals, Inc. Research Report

On August 7, 2013, ARIAD Pharmaceuticals, Inc. (ARIAD) reported its Q2 2013 financial results. The Company's revenue grew to $14 million from $0.3 million in Q2 2012. Net loss was $69 million or $0.37 per diluted share in Q2 2013, compared to net loss of $51.3 million or $0.31 per diluted share in Q2 2012. Commenting on the results, Harvey J. Berger M.D., Chairman and CEO of ARIAD, said, "Our second-quarter results demonstrate strong growth of Iclusig sales in the U.S. During the quarter, we saw a definitive shift in new-patient starts with Iclusig to earlier lines of therapy. We are continuing to build on this robust launch and expect to have between 1,000 and 1,100 patients treated with Iclusig by the end of this year. Additionally, we now have approval of Iclusig in Europe and are working with the national health authorities to obtain reimbursement decisions so that we can make Iclusig available broadly to Philadelphia-positive leukemia patients." The Full Research Report on ARIAD Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-07/ARIA]

--

DexCom, Inc. Research Report

On August 7, 2013, DexCom, Inc. (DexCom) reported its Q2 2013 unaudited financial results. The Company's total revenue increased 53.0% YoY to $35.8 million, with product revenue growing 65.1% YoY to $35.5 million. The Company reported net loss of $10.1 million or $0.14 per diluted share in Q2 2013, compared to a net loss of $14.7 million or $0.21 per diluted share in Q2 2012. The net loss in Q2 2013 included a $9 million non-cash expense, composed primarily of share-based compensation, depreciation, and amortization.The Full Research Report on DexCom, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-07/DXCM]

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


InvestorsReports.com

SOURCE Investors' Reports

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.